Switch theme
Sign up to access all valuation multiples
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
2019
130
LTM Revenue $3.8M
LTM EBITDA -$182M
$5.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zenas BioPharma has a last 12-month revenue of $3.8M and a last 12-month EBITDA of -$182M.
In the most recent fiscal year, Zenas BioPharma achieved revenue of $5.0M and an EBITDA of -$164M.
Zenas BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zenas BioPharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.0M | $5.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$27.0M | -$164M | XXX | XXX | XXX |
| EBITDA Margin | -54% | -3275% | XXX | XXX | XXX |
| Net Profit | -$119M | -$37.1M | XXX | XXX | XXX |
| Net Margin | -239% | -742% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zenas BioPharma's stock price is $9.
Zenas BioPharma has current market cap of $355M, and EV of $5.5M.
See Zenas BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5M | $355M | XXX | XXX | XXX | XXX | $-8.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zenas BioPharma has market cap of $355M and EV of $5.5M.
Zenas BioPharma's trades at 1.5x LTM EV/Revenue multiple, and -0.0x LTM EBITDA.
Analysts estimate Zenas BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zenas BioPharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.5M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | XXX | XXX |
| P/E | -2.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZenas BioPharma's NTM/LTM revenue growth is 123%
Zenas BioPharma's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Zenas BioPharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zenas BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zenas BioPharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -90% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -3275% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 506% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -3152% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $38K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 595% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2783% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 3378% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zenas BioPharma acquired XXX companies to date.
Last acquisition by Zenas BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zenas BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zenas BioPharma founded? | Zenas BioPharma was founded in 2019. |
| Where is Zenas BioPharma headquartered? | Zenas BioPharma is headquartered in United States of America. |
| How many employees does Zenas BioPharma have? | As of today, Zenas BioPharma has 130 employees. |
| Who is the CEO of Zenas BioPharma? | Zenas BioPharma's CEO is Mr. Leon O. Moulder, Jr. |
| Is Zenas BioPharma publicy listed? | Yes, Zenas BioPharma is a public company listed on NAS. |
| What is the stock symbol of Zenas BioPharma? | Zenas BioPharma trades under ZBIO ticker. |
| When did Zenas BioPharma go public? | Zenas BioPharma went public in 2024. |
| Who are competitors of Zenas BioPharma? | Similar companies to Zenas BioPharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zenas BioPharma? | Zenas BioPharma's current market cap is $355M |
| What is the current revenue of Zenas BioPharma? | Zenas BioPharma's last 12-month revenue is $3.8M. |
| What is the current EBITDA of Zenas BioPharma? | Zenas BioPharma's last 12-month EBITDA is -$182M. |
| What is the current EV/Revenue multiple of Zenas BioPharma? | Current revenue multiple of Zenas BioPharma is 1.5x. |
| What is the current EV/EBITDA multiple of Zenas BioPharma? | Current EBITDA multiple of Zenas BioPharma is -0.0x. |
| What is the current revenue growth of Zenas BioPharma? | Zenas BioPharma revenue growth between 2023 and 2024 was -90%. |
| Is Zenas BioPharma profitable? | Yes, Zenas BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
